TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES

Background: Teclistamab is the first approved off-the-shelf BCMA×CD3 bispecific antibody, with personalized weight based dosing, for the treatment of patients (pts) with RRMM based on data from the pivotal phase 1/2 MajesTEC-1 study (NCT03145181/NCT04557098). Moreau et al (NEJM 2022) reported rapid,...

Full description

Bibliographic Details
Main Authors: NWCJV Donk, R Popat, L Rosiol, B Besemer, JM Lopez, D Trancucci, R Verona, T Stephenson, K Chastain, N Bahlis
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S253113792300929X

Similar Items

Similar Items